A new study from Yale University researchers shows how artificial intelligence can bring image, gene and protein data together, offering a clearer picture of what is happening inside the body and how diseases develop.
When a car accident or athletic injury destroys more than 20% of a muscle’s mass, the body faces a problem it often can’t heal fully on its own. Without intervention, scar tissue fills the injury site and can leave patients with permanent weakness and limited mobility.
Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African-American patients survive for half as long as their counterparts of European ancestry, according to a new review study led by researchers from the University of Maryland School of Medicine’s (UMSOM) Institute for Genome Sciences (IGS) and the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC).
Hydrocephalus is a life-threatening condition that occurs in about 1 in 1,000 newborns and is often treated with invasive surgery. Now, a new study offers hope of preventing hydrocephalus before it even occurs. The paper is published in the journal Molecular Therapy.
A tiny roundworm has helped University of Queensland scientists uncover minuscule structures in skin tissue that may protect the body’s ability to feel temperature, touch and pain. The research is published in Science Advances.
Cancer patients who suffer a heart attack face a dangerous mix of risks, which makes their clinical treatment particularly challenging. As a result, patients with cancer have been systematically excluded from many clinical trials and available risk scores. Until now, doctors had no standard tool to guide treatment in this vulnerable group.
Founded by three MIT alumni, Gensaic uses AI-guided protein design to deliver RNA and other therapeutic molecules to specific cells or areas of the body.
Veritas.AI is designed to advance the functionality of Spectrum Dynamics’ VERITON-CT scanner for nuclear imaging.
Rystiggo is administered weekly, 3ml to 6ml over 15 to 30 minutes for six weeks.
MENLO PARK, Calif., Jan. 29, 2026 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the submission of the final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Galleri® multi-cancer early detection (MCED) test. The FDA designated the test as a Breakthrough Device in 2018.